# Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

> **NCT01950455** · PHASE3 · TERMINATED · sponsor: **Navidea Biopharmaceuticals** · enrollment: 13 (actual)

## Conditions studied

- Parkinson's Syndrome

## Interventions

- **DRUG:** NAV5001

## Key facts

- **NCT ID:** NCT01950455
- **Lead sponsor:** Navidea Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11
- **Primary completion:** 2018-01
- **Final completion:** 2018-01
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** The entire drug development program for this molecule was sold to another company.
- **Last updated:** 2018-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01950455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01950455, "Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01950455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*